Nutritional and Metabolic Disorders in Parkinson’s Disease

Authors: J. Picmausová 1;  M. Haluzík 2 ;  E. Růžička 1
Authors‘ workplace: 1. LF UK a VFN v Praze Neurologická klinika a Centrum klinických neurověd 1;  1. LF UK a VFN v Praze III. interní klinika 2
Published in: Cesk Slov Neurol N 2012; 75/108(2): 179-184
Category: Review Article


Parkinson’s disease is a chronic neurodegenerative disease, characterized by progressive loss of nigrostratal dopaminergic neurons and other ascendant systems of the brainstem. Apart from typical motor signs, patients complain of various non-motor symptoms, including autonomic dysfunction and nutritional and metabolic disorders. The purpose of this paper is to summarize current knowledge about nutritional and metabolic disorders in patients with Parkinson’s disease and about their possible causes, namely changes of energy output, malfunction of the gastrointestinal tract, hyposmia, endocrinological disorders, depression, dementia and therapeutic factors. The disease progression is usually associated with weight loss of an unclear etiology. Hence, we emphasize the importance of further research as well as the improvement of nutritional care of patients as a prevention of complications due to malnutrition.

Key words:
Parkinson’s disease – neurodegeneration – autonomic dysfunction – metabolism – nutrition


1. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24(2): 197–211.

2. Braak H, Bohl JR, Muller CM, Rub U, de Vos RA, Del Tredici K. Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson’s disease reconsidered. Mov Disord 2006; 21(12): 2042–2051.

3. Delikanaki-Skaribas E, Trail M, Wong WW, Lai EC. Daily energy expenditure, physical activity, and weight loss in Parkinson’s disease patients. Mov Disord 2009; 24(5): 667–671.

4. Uc EY, Struck LK, Rodnitzky RL, Zimmerman B, Dobson J, Evans WJ. Predictors of weight loss in Parkinson’s disease. Mov Disord 2006; 21(7): 930–936.

5. Barichella M, Cereda E, Pezzoli G. Major nutritional issues in the management of Parkinson’s disease. Mov Disord 2009; 24(13): 1881–1892.

6. Bachmann CG, Trenkwalder C. Body weight in patients with Parkinson’s disease. Mov Disord 2006; 21(11): 1824–1830.

7. Kashihara K. Weight loss in Parkinson’s disease. J Neurol 2006; 253 (Suppl 7): VII38–VII41.

8. Chen H, Zhang SM, Hernan MA, Willett WC, Ascherio A. Weight loss in Parkinson’s disease. Ann Neurol 2003; 53(5): 676–679.

9. Barichella M, Marczewska A, Vairo A, Canesi M, Pezzoli G. Is underweightness still a major problem in Parkinson’s disease patients?. Eur J Clin Nutr 2003; 57(4): 543–547.

10. Lorefält B, Toss G, Granerus AK. Weight loss, body fat mass, and leptin in Parkinson’s disease. Mov Disord 2009; 24(6): 885–890.

11. Levi S, Cox M, Lugon M, Hodkinson M, Tomkins A. Increased energy expenditure in Parkinson’s disease. BMJ 1990; 301(6763): 1256–1257.

12. Toth MJ, Fishman PS, Poehlman ET. Free-living daily energy expenditure in patients with Parkinson’s disease. Neurology 1997; 48(1): 88–91.

13. Jost WH. Gastrointestinal dysfunction in Parkinson’s Disease. J Neurol Sci 2010; 289(1–2): 69–73.

14. Anderson G, Noorian AR, Taylor G, Anitha M, Bern­hard D, Srinivasan S et al. Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson’s disease. Exp Neurol 2007; 207(1): 4–12.

15. Blandini F, Balestra B, Levandis G, Cervio M, Greco R, Tassorelli C et al. Functional and neurochemical changes of the gastrointestinal tract in a rodent model of Parkinson’s disease. Neurosci Lett 2009; 467(3): 203–207.

16. Felix VN, Correa SM, Soares RJ. A therapeutic maneuver for oropharyngeal dysphagia in patients with Parkinson’s disease. Clinics (Sao Paulo) 2008; 63(5): 661–666.

17. Lim A, Leow L, Huckabee ML, Frampton C, Anderson T. A pilot study of respiration and swallowing integration in Parkinson’s disease: “on” and “off” levodopa. Dysphagia 2008; 23(1): 76–81.

18. Volonte MA, Porta M, Comi G. Clinical assessment of dysphagia in early phases of Parkinson’s disease. Neurol Sci 2002; 23 (Suppl 2): S121–S122.

19. Monte FS, da Silva-Junior FP, Braga-Neto P, Nobre e Souza MA, de Bruin VM. Swallowing abnormalities and dyskinesia in Parkinson’s disease. Mov Disord 2005; 20(4): 457–462.

20. Tjaden K. Speech and Swallowing in Parkinson’s Disease. Top Geriatr Rehabil 2008; 24(2): 115–126.

21. Edwards LL, Quigley EM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease: frequency and pathophysiology. Neurology 1992; 42(4): 726–732.

22. Goetze O, Nikodem AB, Wiezcorek J, Banasch M, Przuntek H, Mueller T et al. Predictors of gastric emptying in Parkinson’s disease. Neurogastroenterol Motil 2006; 18(5): 369–375.

23. Sakakibara Y, Asahina M, Suzuki A, Hattori T. Gastric myoelectrical differences between Parkinson’s disease and multiple system atrophy. Mov Disord 2009; 24(11): 1579–1586.

24. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett 2006; 396(1): 67–72.

25. Barichella M, Savardi C, Mauri A, Marczewska A, Vairo A, Baldo C et al. Diet with LPP for renal pa­tients increases daily energy expenditure and improves motor function in parkinsonian patients with motor fluctuations. Nutr Neurosci 2007; 10(3–4): 129–135.

26. Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T et al. Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009; 24(10): 1468–1474.

27. Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci 2002; 14(2): 223–236.

28. Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD et al. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 2001; 57(3): 456–462.

29. Pfeiffer RF. Non-motor parkinsonism. Parkinsonism Relat Disord 2007; 13 (Suppl 3): S211–220.

30. Tolosa E, Compta Y, Gaig C. The premotor phase of Parkinson’s disease. Parkinsonism Relat Disord 2007; 13 (Suppl 3): S2–7.

31. Lerner A, Bagic A. Olfactory pathogenesis of idio­pathic Parkinson disease revisited. Mov Disord 2008; 23(8): 1076–1084.

32. Evidente VG, Caviness JN, Adler CH, Gwinn--Hardy KA, Pratley RE. Serum leptin concentra­tions and satiety in Parkinson’s disease patients with and without weight loss. Mov Disord 2001; 16(5): 924–927.

33. Palmiter RD. Is dopamine a physiologically relevant mediator of feeding behavior? Trends Neurosci 2007; 30(8): 375–381.

34. Drouot X, Moutereau S, Nguyen JP, Lefaucheur JP, Creange A, Remy P et al. Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology 2003; 61(4): 540–543.

35. Cannizzaro C, Tel BC, Rose S, Zeng BY, Jenner P. Increased neuropeptide Y mRNA expression in striatum in Parkinson’s disease. Brain Res Mol Brain Res 2003; 110(2): 169–176.

36. Triantafyllou NI, Nikolaou C, Boufidou F, Angelopoulos E, Rentzos M, Kararizou E et al. Folate and vitamin B12 levels in levodopa-treated Parkinson’s disease patients: their relationship to clinical manifestations, mood and cognition. Parkinsonism Relat Disord 2008; 14(4): 321–325.

37. Wang G, Wan Y, Cheng Q, Xiao Q, Wang Y, Zhang J et al. Malnutrition and associated factors in Chinese patients with Parkinson’s disease: Results from a pilot investigation. Parkinsonism Relat Disord 2010; 16(2): 119–23.

38. Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66(7): 996–1002.

39. Adler CH. Nonmotor complications in Parkinson’s disease. Mov Disord 2005; 20 (Suppl 11): S23–S29.

40. Kumru H, Santamaria J, Valldeoriola F, Marti MJ, Tolosa E. Increase in body weight after pramipexole treatment in Parkinson’s disease. Mov Disord 2006; 21(11): 1972–1974.

41. Montaurier C, Morio B, Bannier S, Derost P, Arnaud P, Brandolini-Bunlon M et al. Mechanisms of body weight gain in patients with Parkinson’s disease after subthalamic stimulation. Brain 2007; 130(7): 1808–1818.

42. Walker HC, Lyerly M, Cutter G, Hagood J, Stover NP, Guthrie SL et al. Weight changes associated with unilateral STN DBS and advanced PD. Parkinsonism Relat Disord 2009; 15(9): 709–711.

43. Novakova L, Ruzicka E, Jech R, Serranova T, Dusek P, Urgosik D. Increase in body weight is a non-motor side effect of deep brain stimulation of the subthalamic nucleus in Parkinson’s disease. Neuro Endocrinol Lett 2007; 28(1): 21–25.

44. Sauleau P, Leray E, Rouaud T, Drapier S, Drapier D, Blanchard S et al. Comparison of weight gain and energy intake after subthalamic versus pallidal stimulation in Parkinson’s disease. Mov Disord 2009; 24(14): 2149–2155.

Paediatric neurology Neurosurgery Neurology

Article was published in

Czech and Slovak Neurology and Neurosurgery

Issue 2

2012 Issue 2

Most read in this issue
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account